AACR 2021 | PSMA dRT: PSMA PET/CT before radiotherapy in prostate cancer
Jeremie Calais, MD, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, gives an overview of the study protocol for the Phase II PSMA-dRT trial (NCT04457245) of prostate-specific membrane antigen (PSMA) PET/CT before definitive radiation therapy for patients with intermediate- or high-risk prostate cancer. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.
Disclosures
Jeremie Calais, MD, has received honoraria from Advanced Accelerator Applications, Blue Earth Diagnostics, Curium Pharma, GE Healthcare, IBA RadioPharma, Janssen Pharmaceuticals, POINT biopharma, Progenics/Lantheus, Radiomedix and Telix Pharmaceuticals; has participated in consultancy work with Blue Earth Diagnostics, Curium Pharma, GE Healthcare, Janssen Pharmaceuticals, POINT biopharma and Progenics/Lantheus; has participated in a speaker role for IBA RadioPharma and Telix Pharmaceuticals; has acted as a blinded independent central reader for Advanced Accelerator Applications, Progenics/Lantheus and Radiomedix, and has received research support from Progenics/Lantheus.
